Clinical and economic comparison of lenograstim-primed blood cells (BC) and bone marrow (BM) allogeneic transplantation

Bone Marrow Transplantation

Volumn 21, Issue SUPPL. 3, 1998, Pages

  Faucher, C ^a   Fortanier, C ^b   Viens, P ^a   Le Corroller, A G ^b   Chabannon, C ^a   Camerlo, J ^a   Novakovitch, G ^a   Gastaut, J A ^a   Maraninchi, D ^a   Moatti, J P ^a   Blaise, D ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b INSERM   (France)

Author keywords

Allogeneic transplantation; Bone marrow; Cost comparison; rhG CSF primed blood cells

Indexed keywords

CD3 ANTIGEN; CD34 ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; BONE PAIN; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HEALTH CARE COST; HEALTH ECONOMICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; MALE; MEDICAL RECORD; NEUTROPHIL; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; BONE MARROW TRANSPLANTATION; COSTS AND COST ANALYSIS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0031872282     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Sheridan WP, Begley CG, Juttner CA et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-644.
2. Faucher C, Le Corroller AG, Chabannon C et al. Autologous transplantation with G-CSF primed peripheral blood progenitor cells (PBPC). Bone Marrow Transplant 1995; 15 (Suppl. 2): S34.
3. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
4. Hartmann O, Le Corroller AG, Blaise D et al. Clinical and economic results of a multicentric randomized trial comparing peripheral blood stem cells and bone marrow graft in autologous transplantation. Ann Intern Med 1997; 126: 600-607.
5. Weaver CH, Buckner CD, Longin K et al. Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Blood 1993; 82: 1981-1984.
6. Matsunaga T, Sakamaki S, Kongo Y et al. Recombinant human granulocyte colony-stimulating factor can mobilize sufficient amounts of peripheral blood stem cells in healthy volunteers for allogeneic transplantation. Bone Marrow Transplant 1993; 11: 103.
7. Körbling M, Prezpiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
8. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
9. Bensinger WI, Weaver CH, Appelbaum F et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor (rhG-CSF). Blood 1995; 85: 1655-1658.
10. Bensinger WI, Clift R, Martin P et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996; 88: 2794-2800.
11. Chabannon C, Le Corroller AG, Faucher C et al. Patient condition affects the collection of peripheral blood progenitors after priming with recombinant granulocyte colony-stimulating factor. J Hematother 1995; 4: 171-179.
12. Przepiorka D, Weisdorf D, Martin P et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
13. Finkler SA. The distinction between cost and charge. Ann Intern Med 1982; 96: 102-109.
14. Eisenberg JM. New drug and clinical economics: analysis of cost-effectiveness in the assessment of pharmaceutical innovations. Rev Infect Dis 1984; 6: S905-S909.
15. SPSS for Windows. User's guide. 6.0 edn. 1993.
16. Bensinger WI, Price TH, Dale DC et al. The effects of daily recombinant human granulocyte colony stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993; 81: 1883-1888.
17. + Thy1) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995; 86: 2842-2848.
18. Jansen J, Goselink HM, Veenhof WFJ et al. The impact of the composition of the bone marrow graft on engraftment and graft-versus-host-disease. Exp Hematol 1983; 11: 967-973.
19. Pan L, Delmont J, Jalonen CK et al. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokin production and reduces severity of experimental graft versus host disease. Blood 1995; 86: 4422-4430.
20. Talmadge JE, Reed EC, Kessinger A et al. Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant 1996; 17: 101.
21. Urbano-Ispizua A, Garcia-Conde J, Brunet S et al. High incidence of chronic graft versus host disease (GVHD) after allogeneic peripheral blood progenitor cell transplantation (allo-PBPCT) from matched related donors. Blood 1996; 88 (Suppl. 1): 617a (Abstr. 2455).
22. Viens-Bitker C, Fery-Lemonnier E, Blum-Boisgard C. Cost of allogeneic bone marrow transplantation in four diseases. Health Policy 1989; 12: 309-317.
23. Barr R, Furlong W, Henwood J et al. Economic evaluation of allogeneic bone marrow transplantation: a rudimentary model to generate estimates for the timely formulation of clinical policy. J Clin Oncol 1996; 14: 1413-1420.
24. Dufoir T, Saux MC, Marit G et al. Comparative cost of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission. Bone Marrow Transplant 1992; 10: 323-329.
25. Kay H, Lawler S, Powles R et al. Cost of bone-marrow transplants in acute myeloid leukaemia. Lancet 1980; 17: 1067-1069.
26. Griffiths RI, Bass EB, Powe NR et al. Factors influencing third party payer costs for allogeneic BMT. Bone Marrow Transplant 1993; 12: 43-18.
27. Drummond MF, Menzin J, Oster G. Methodological issues in economic assessment of new therapies: the case of colony-stimulating factors. PhannacoEconomics 1994; 6 (Suppl. 2): 18-26.